Aquestive Therapeutics, Inc. (AQST) Stock AnalysisAQSTAquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Aquestive Therapeutics Inc is not a strong buy due to its ongoing financial struggles and recent insider selling, despite some positive catalysts. The stock is priced at $4.78, with an RSI of 62.56 indicating it is nearing overbought territory. The forward P/E ratio is currently at 0, suggesting uncertainty about future earnings. However, the gross margin has improved significantly to 75.99% in Q1 2026, indicating potential for profitability if revenue continues to grow. The main risk is the legal investigation into the company, which could negatively impact investor sentiment and stock price.

4 analysts cover AQST: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.00.